Cover Image
市場調查報告書

酪胺酸-蛋白質激酶BKT (Breton型無伽馬球蛋白血症蛋白酪氨酸激酶,B細胞前驅細胞激酶,無γ球朊血症蛋白酪氨酸激酶,EC 2.7.10.2):開發中產品分析

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363569
出版日期 內容資訊 英文 138 Pages
訂單完成後即時交付
價格
Back to Top
酪胺酸-蛋白質激酶BKT (Breton型無伽馬球蛋白血症蛋白酪氨酸激酶,B細胞前驅細胞激酶,無γ球朊血症蛋白酪氨酸激酶,EC 2.7.10.2):開發中產品分析 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 138 Pages
簡介

本報告提供全球各國的酪胺酸-蛋白質激酶BKT (別名Breton型無伽馬球蛋白血症蛋白酪氨酸激酶,B細胞前驅細胞激酶,無γ球朊血症蛋白酪氨酸激酶,EC 2.7.10.2) 相關的開發中產品的開發情形分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • 酪胺酸-蛋白質激酶BKT (Breton型無伽馬球蛋白血症蛋白酪氨酸激酶、B細胞前驅細胞激酶、無γ球朊血症蛋白酪氨酸激酶、EC 2.7.10.2)的概要
  • 治療藥的開發情形
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 各大學、研究機關開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • AbbVie Inc.
    • Advinus Therapeutics Ltd
    • ArQule, Inc.
    • BeiGene, Ltd.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • CrystalGenomics, Inc.
    • Genentech, Inc.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • LSK BioPartners, Inc.
    • Merck KGaA
    • 小野藥品工業
    • Pharmacyclics, Inc.
    • Principia Biopharma Inc.
    • Redx Pharma Plc
    • Simcere Pharmaceutical Group
    • Sunesis Pharmaceuticals, Inc.
    • 武田藥品工業
  • 藥物簡介
    • acalabrutinib
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • X連鎖無伽馬球蛋白血症的BKT活性化用反義寡核苷酸
    • ARQ-531
    • BGB-3111
    • CG-026806
    • CG-036806
    • 未公開症狀的BKT抑制劑
    • EBI-1266
    • EBI-1367
    • HCI-1401
    • HCI-1684
    • HM-71224
    • ibrutinib
    • M-2951
    • M-7583
    • ONO-4059
    • PLS-123
    • PNQ-154
    • PNQ-849
    • PRN-1008
    • PRN-473
    • RDX-002
    • RG-7845
    • 關節炎的Breton型蛋白酪氨酸激酶抑制用小分子
    • 發炎的Breton型蛋白酪氨酸激酶抑制用小分子
    • 免疫疾病的BKT抑制用小分子
    • 發炎、自體免疫疾病、癌症的BKT抑制用小分子
    • 腫瘤的BKT抑制用小分子
    • 腫瘤的BKT抑制用小分子
    • 類風濕性關節炎的BKT抑制用小分子
    • SNS-062
    • spebrutinib besylate
    • TAK-020
    • X-022
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (共15件)
  • 附錄

圖表一覽

目錄
Product Code: GMDHC0101TDB

Summary

Global Markets Direct's, 'Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016', provides in depth analysis on Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2)
  • The report reviews Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Overview
  • Therapeutics Development
    • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Stage of Development
    • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Therapy Area
    • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Indication
  • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Companies
  • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Universities/Institutes
  • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Advinus Therapeutics Ltd
    • ArQule, Inc.
    • BeiGene, Ltd.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • CrystalGenomics, Inc.
    • Genentech, Inc.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • LSK BioPartners, Inc.
    • Merck KGaA
    • Ono Pharmaceutical Co., Ltd.
    • Pharmacyclics, Inc.
    • Principia Biopharma Inc.
    • Redx Pharma Plc
    • Simcere Pharmaceutical Group
    • Sunesis Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
  • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Drug Profiles
    • acalabrutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotides to Activate BTK for X-linked Agammaglobulinemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARQ-531 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGB-3111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-026806 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-036806 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit BTK for Undisclosed Indications - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EBI-1266 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EBI-1367 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HCI-1401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HCI-1684 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HM-71224 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibrutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-2951 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-7583 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-4059 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLS-123 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNQ-154 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNQ-849 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRN-1008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRN-473 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RDX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7845 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Bruton Tyrosine Kinase for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit BTK for Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit BTK for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit BTK for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit BTK for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SNS-062 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • spebrutinib besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • X-022 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Dormant Projects
  • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Discontinued Products
  • Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Featured News & Press Releases
    • Jun 06, 2016: AbbVie Builds Upon Robust Body of IMBRUVICA (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology Annual Meeting
    • Jun 01, 2016: NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund
    • May 31, 2016: Janssen's IMBRUVICA (ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia
    • May 24, 2016: REDX PHARMA: Proof of concept with key oncology lead
    • May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016
    • May 18, 2016: Janssen to Present Data on Ibrutinib at the 2016 American Society of Clinical Oncology Annual Meeting
    • May 12, 2016: Health Canada Approves IMBRUVICA (ibrutinib) for the Treatment of Waldenstroms Macroglobulinemia
    • May 09, 2016: U.S. FDA Expands IMBRUVICA (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia and New Indication for Small Lymphocytic Lymphoma Patients
    • Apr 29, 2016: European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients
    • Apr 29, 2016: Janssen's IMBRUVICA (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients
    • Mar 23, 2016: Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062
    • Mar 14, 2016: Diplomat Now Dispensing IMBRUVICA as First-Line Therapy for Chronic Lymphocytic Leukemia
    • Mar 07, 2016: BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111
    • Mar 04, 2016: U.S. FDA Approves IMBRUVICA (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia
    • Feb 25, 2016: Acalabrutinib recommended for orphan drug designation in Europe for three indications
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by AbbVie Inc., H1 2016
  • Pipeline by Advinus Therapeutics Ltd, H1 2016
  • Pipeline by ArQule, Inc., H1 2016
  • Pipeline by BeiGene, Ltd., H1 2016
  • Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Pipeline by Celgene Corporation, H1 2016
  • Pipeline by CrystalGenomics, Inc., H1 2016
  • Pipeline by Genentech, Inc., H1 2016
  • Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Pipeline by LSK BioPartners, Inc., H1 2016
  • Pipeline by Merck KGaA, H1 2016
  • Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Pipeline by Pharmacyclics, Inc., H1 2016
  • Pipeline by Principia Biopharma Inc., H1 2016
  • Pipeline by Redx Pharma Plc, H1 2016
  • Pipeline by Simcere Pharmaceutical Group, H1 2016
  • Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top